[go: up one dir, main page]

UA93181C2 - СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ - Google Patents

СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ

Info

Publication number
UA93181C2
UA93181C2 UAA200609258A UAA200609258A UA93181C2 UA 93181 C2 UA93181 C2 UA 93181C2 UA A200609258 A UAA200609258 A UA A200609258A UA A200609258 A UAA200609258 A UA A200609258A UA 93181 C2 UA93181 C2 UA 93181C2
Authority
UA
Ukraine
Prior art keywords
antibody
preparing
cells
peptide
endogenously
Prior art date
Application number
UAA200609258A
Other languages
English (en)
Ukrainian (uk)
Inventor
Рональд Брендли Дематтос
Ума Кучиботла
Хсю-Чунг Янг
Дон Б. Макклюр
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of UA93181C2 publication Critical patent/UA93181C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Изобретение относится к способу получения антитела к амиоидному пептиду (Аβ), который включает экспрессирование антитела в клетках, которые эндогенно экспрессируют Аβ пептид, добавление ингибитора гамма-сектертазы в питательную среду, которая применяется для выращивания упомянутых клеток, и очищение антитела от упомянутой питательной среды, так чтобы содержание Аβ пептида в очищенном антителе составляло не более чем 0,02 нг/мл.
UAA200609258A 2004-02-23 2005-02-17 СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ UA93181C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23

Publications (1)

Publication Number Publication Date
UA93181C2 true UA93181C2 (ru) 2011-01-25

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200609258A UA93181C2 (ru) 2004-02-23 2005-02-17 СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ

Country Status (20)

Country Link
US (1) US20070190046A1 (ru)
EP (1) EP1720909B1 (ru)
JP (1) JP4851348B2 (ru)
KR (2) KR20090005410A (ru)
CN (1) CN1922209B (ru)
AT (1) ATE534667T1 (ru)
AU (1) AU2005217596B2 (ru)
BR (1) BRPI0507856A (ru)
CA (1) CA2556436C (ru)
CY (1) CY1112162T1 (ru)
DK (1) DK1720909T3 (ru)
EA (1) EA009872B1 (ru)
ES (1) ES2375627T3 (ru)
IL (1) IL177611A (ru)
NO (1) NO20064239L (ru)
PL (1) PL1720909T3 (ru)
PT (1) PT1720909E (ru)
SI (1) SI1720909T1 (ru)
UA (1) UA93181C2 (ru)
WO (1) WO2005082939A2 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
NZ568012A (en) 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
PL2046833T3 (pl) 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
DK2099826T3 (da) * 2007-01-05 2014-01-20 Univ Zuerich Anti-beta-amyloid-antistof og anvendelser deraf
TW200844110A (en) 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US20100297012A1 (en) * 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
BRPI0921837A2 (pt) 2008-11-25 2016-01-12 Biogen Idec Inc anticorpos isolados ou fragmentos de antígeno de ligação dos mesmos que podem se ligar especificamente a um polipeptídio dr6, métodos in vitro de promover a sobrevivência de uma célula do sistema nervoso, usos de um antagonista dr6 e métodos in vitro de inibir a ligação de dr6 com p75
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
TW201121570A (en) 2009-11-12 2011-07-01 Genentech Inc A method of promoting dendritic spine density
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
EP3042917B1 (en) * 2010-08-12 2018-02-21 Eli Lilly and Company Anti-n3pglu amyloid beta peptide antibodies and uses thereof
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
EA030777B9 (ru) 2011-06-23 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Анти-альфа-синуклеинсвязывающие молекулы
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
AU2013312358B2 (en) 2012-09-07 2018-08-09 Massachusetts Eye & Ear Infirmary Treating hearing loss
IL320195A (en) 2013-09-13 2025-06-01 Genentech Inc Methods and compositions containing purified recombinant polypeptides
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
EP3497105A1 (en) * 2016-08-11 2019-06-19 Eli Lilly And Company Aminothiazines and their use as bace1 inhibitors
PL3672631T3 (pl) 2017-08-22 2023-06-26 Biogen Ma Inc. Kompozycje farmaceutyczne zawierające przeciwciała przeciw beta-amyloidowi
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
MX2024009597A (es) 2022-02-03 2024-08-15 Lilly Co Eli Imagenologia de tau regional para diagnosticar y tratar la enfermedad de alzheimer.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU749658C (en) 1996-12-23 2004-04-29 Elan Pharmaceuticals, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
DZ3295A1 (fr) * 2000-02-24 2001-08-30 Anticorps humanises sequestrant un peptide amyloide .beta.
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ATE420114T1 (de) * 2001-04-30 2009-01-15 Lilly Co Eli Humanisierte antikörper die das beta-amyloid peptid erkennen& x9;

Also Published As

Publication number Publication date
WO2005082939A3 (en) 2005-10-27
EA200601545A1 (ru) 2007-02-27
CA2556436C (en) 2014-04-01
WO2005082939A2 (en) 2005-09-09
JP4851348B2 (ja) 2012-01-11
KR100889430B1 (ko) 2009-03-23
CY1112162T1 (el) 2015-12-09
SI1720909T1 (sl) 2012-01-31
EP1720909B1 (en) 2011-11-23
CN1922209A (zh) 2007-02-28
JP2008500279A (ja) 2008-01-10
CA2556436A1 (en) 2005-09-09
BRPI0507856A (pt) 2007-07-10
DK1720909T3 (da) 2012-01-30
PL1720909T3 (pl) 2012-04-30
KR20090005410A (ko) 2009-01-13
KR20060126785A (ko) 2006-12-08
US20070190046A1 (en) 2007-08-16
CN1922209B (zh) 2012-09-05
AU2005217596B2 (en) 2012-01-19
EP1720909A2 (en) 2006-11-15
PT1720909E (pt) 2011-12-23
ATE534667T1 (de) 2011-12-15
ES2375627T3 (es) 2012-03-02
IL177611A (en) 2013-05-30
NO20064239L (no) 2006-11-20
EA009872B1 (ru) 2008-04-28
IL177611A0 (en) 2006-12-10
AU2005217596A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
UA93181C2 (ru) СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ
SG149061A1 (en) Definitive endoderm
MX2020001944A (es) Poblaciones de celula madre de la placenta.
MX2009010361A (es) Anticuerpos il-12 anti-humanos cristalinos.
MX2009002991A (es) Indicador de esterilizacion.
TW200631917A (en) Synthetic aggregates comprising sewage sludge and other waste materials and methods for producing such aggregates
MX2010000348A (es) Cultivo de celulas madre pluripotentes individuales.
SG138449A1 (en) Enumeration method for the link clock rate and the pixel/audio clock rate
MX2009004351A (es) Anticuerpos anti-htnfalfa cristalinos.
MX2010006576A (es) Composiciones y metodos para producir isopreno.
WO2008009639A3 (en) New indications for direct thrombin inhibitors
PT1974017E (pt) Meios e métodos para influenciar a estabilidade de células produtoras de anticorpo
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
EA201070774A1 (ru) Цеолит типа lsx с контролируемой гранулометрией
AU2019268061A1 (en) Placental stem cell populations
DE502005004058D1 (de) Verfahren zur deacylierung von lipopeptiden
DE602006010400D1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
CY1112973T1 (el) Περαιτερω κρυσταλλικες μορφες ροσταφουροξινης
PH12021550950A1 (en) Method for culturing cord blood-derived natural killer cells using transformed t cells
BRPI0509302A (pt) método de purificação de oócitos de uma composição que compreende material fecal
PH12016501302A1 (en) Method for the prepartion of biopolymers
TN2009000147A1 (en) Crystal modifications -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-d ione
WO2004016743A3 (en) Culturing anaplasma
DK1651754T3 (da) Myelomcellekultur i transferrinfrit medium med lavt jernindhold
WO2008052803A3 (en) Zeolite crystals with biological material